Trial · NCT03193190
Adverse events6,528
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 6,528
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 14 | 32 | 15 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 4 | 9 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 10 | 25 | 11 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 9 | 15 | 9 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | 13 | 41 | 19 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | 6 | 30 | 6 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | 4 | 23 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | 6 | 23 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Atezolizumab + BL-8040 | 3 | 15 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | 2 | 14 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | 8 | 66 | 9 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | 1 | 15 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | 1 | 14 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | 3 | 14 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | 2 | 6 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W | 0 | 1 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 2 | 32 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 0 | 9 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 1 | 25 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 0 | 15 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03193190/events